The novel anticancer drug oracin: Different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11β-hydroxysteroid dehydrogenase type 1

Toxicology

Volumn 197, Issue 3, 2004, Pages 253-261

  Wsól, Vladimír ^a,b   Szotáková, Barbora ^a,b   Skálová, Lenka ^a   Maser, Edmund ^b,c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

11 HSD 1; 11 hydroxysteroid dehydrogenase type 1; 6 2 (2 hydroxyethyl)aminoethyl 5 oxo 11 hydroxy 5,6 dihydro 11H indeno 1,2 c isoquinoline; BL; Burkitt's lymphoma; Chirality; Cytostatics; DHO; Drug metabolism; Microsomes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANTIINFECTIVE AGENT; CARBONYL DERIVATIVE; ORACIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CATALYSIS; CHEMICAL REACTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HUMAN TISSUE; LIVER; MICROSOME; PRIORITY JOURNAL; REDUCTION; STEREOSPECIFICITY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; ETHANOLAMINES; HUMANS; ISOQUINOLINES; MICROSOMES, LIVER; STEREOISOMERISM;

EID: 1642323738     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2004.01.009     Document Type: Article

References (33)

1. Ax W., Soldan M., Koch L., Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59:2000;293-300.
2. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu. Rev. Immunol. 52:1995;513-543.
3. Davankov V. The nature of chiral recognition: is it a three-point interaction? Chirality. 9:1997;99-102.
4. Fisher T.C., Milner A.E., Gregory C.D., Jackman A.L., Aherne G.W., Hartley J.A., Dive C., Hickman J.A. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 53:1993;3321-3326.
5. Forrest G.L., Gonzalez B., Tseng W., Lim X., Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60:2000;5158-5164.
6. Gersl V., Mazurová Y., Bajgar J., Melka M., Hrdina R., Palicka V. Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch. Toxicol. 70:1996;645-651.
7. Gillette, J.R., 1972. Techniques for studying drug metabolism in vitro. in: La Du, B.N., Mandel, H.G., Way, E.L. (Eds.), Fundamentals of Drug Metabolism and Drug Disposition. The Williams and Wilkins Company, Baltimore, pp. 400-418.
8. Gonzalez B., Akman S., Doroshow J., Rivera H., Kaplan W.D., Forrest G.L. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 55:1995;4646-4650.
9. Klucar J., Al-Rubeai M. G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. FEBS Lett. 400:1997;127-130.
10. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
11. Licata S., Saponieri A., Mordente A., Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem. Res. Toxicol. 13:2000;414-420.
12. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
13. Marhan J. Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test. Folia Microbiol. 40:1995;457-461.
14. Maser E. 11β-Hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK) in mouse lung microsomes. Cancer Res. 58:1998a;2996-3003.
15. Maser E. 11β-Hydroxysteroid dehydrogenase: another steroid metabolizing enzyme involved in detoxification processes. Res. Trends. 1:1998b;37-57.
16. Maser E., Bannenberg G. 11β-Hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem. Pharmacol. 47:1994;1805-1812.
17. Maser E., Richter E., Friebertshäuser J. The identification of 11β-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Eur. J. Biochem. 238:1996;484-489.
18. Maser E., Völker B., Friebertshäuser J. 11β- Hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry. 41:2002;2459-2465.
19. Melka, M., 1993. Oracin - preclinical summary report of the Research Institute for Pharmacy and Biochemistry. Prague, Czech Republic.
20. Michalský, J., 1992. International Patent Application. PCT/CS92/00026.
21. Miko M., Poturnajová M., Soucek R. Cytotoxicity and mode of action of the potential cytostatic drug oracin. Neoplasma. 49:2002;167-1671.
22. Minotti G., Licata S., Saponiero A., Menna P., Calofiore A.M., Di Giammarco G., Liberi G., Animati F., Cipollone A., Manzini S., Maggi C.A. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem. Res. Toxicol. 13:2000;1336-1341.
23. Pröpper D., Maser E. Carbonyl reduction of daunorubicin in rabbit liver and heart. Pharmacol. Toxicol. 80:1997;240-245.
24. Seckl J.R., Walker B.R. Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology. 142:2001;1371-1376.
25. Skálová L., Nobilis M., Szotáková B., Kondrová E., Savlík M., Wsól V., Pichard Garcia L., Maser E. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro. Biochem. Pharmacol. 64:2002;297-305.
26. Soldan M., Netter K.J., Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive end resistant pancreas carcinoma cells. Biochem. Pharmacol. 51:1996;117-123.
27. Szotáková B., Skálová L., Wsól V., Kvasnicková E. Reduction of the potential anticancer drug oracin in the rat liver in vitro. J. Pharm. Pharmacol. 52:2000;495-500.
28. Szotáková B., Wsól V., Trejtnar F., Skálová L., Kvasnicková E. Studies on the metabolism of the potential cytostatic drug oracin. Species differences. Exp. Toxicol. Pathol. 48(Suppl. II):1996;377-380.
29. Wsól V., Kvasnicková E., Szotáková B., Hais I.M. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracin. J. Chromatogr. B. 681:1996;169-175.
30. Wsól V., Skálová L., Szotáková B., Trejtnar F., Kvasnicková E. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo. Chirality. 11:1999;505-509.
31. Wsól V., Szotáková B., Kvasnicková E., Fell A.F. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison. J. Chromatogr. A. 797:1998;197-201.
32. Wsól V., Szotáková B., Skálová L., Cepková H., Kvasnicková E. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. Enantiomer. 5:2000;263-270.
33. Wsól V., Szotáková B., Skálová L., Maser E. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11β-hydroxysteroid dehydrogenase type 1. Chem.-Biol. Interact. 143-144:2003;459-468.